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This	  is	  a	  observational	  (cross	  sectional)	  study	  investigating	  gastrointestinal	  hypomotility	  caused	  
by	   antispychotic	   medication,	   an	   important	   adverse	   effect	   spectrum	   that	   has	   caused	  
considerable	  morbidity	  and	  mortality	  amongst	  antipsychotic-­‐treated	  patients.	  	  
In	   New	   Zealand	   over	   the	   last	   decade	   at	   least	   36	   patients	   have	   developed	   life	   threatening	  
gastrointestinal	  motility	  problems	  related	  to	  antipsychotics	   (clozapine),	  of	  whom	  11	  have	  died	  
(personal	   correspondence,	   Janelle	   Ashton,	   NZ	   pharmacovigilance	   centre).	   Some	   of	   these	  
patients	  were	  in	  their	  twenties	  with	  no	  other	  comorbidities.	  
Although	   there	   is	   a	   growing	   body	   of	   literature	   on	   this	   topic,	   the	   effects	   of	   antipsychotics	   on	  
gastrointestinal	   motility	   are	   speculative,	   and	   have	   not	   been	   quantified.	   	   This	   can	   be	   done	  
through	  astrointestinal	  motility	  studies	  using	  radiopaque	  markers,	  which	  are	  well	  tolerated	  and	  
cost	  effective.	  
The	  development	  of	  this	  research	  protocol	  has	   involved	   input	  and	  support	   from	  four	  different	  
disciplines:	  psychiatry;	  radiology;	  gastroenterology	  and	  pharmacology.	  The	  research	  project	  has	  





SECTION	  1:	  RESEARCH	  QUESTION	  AND	  BACKGROUND	  
	  
Research	  Questions	  
In	   antipsychotic-­‐treated	   psychiatric	   inpatients,	   how	   does	   gastrointestinal	   motility	   (as	  
measured	   by	   radiopaque	   marker	   (ROM)	   transit	   studies	   (described	   below)	   compare	   with	  
standardised	  normative	  values?	  	  
	  
Does	   colonic	   transit	   time	   differ	   significantly	   between	   people	   treated	   with	   clozapine	   and	  
treated	  with	  other	  antipsychotics?	  
	  
How	  are	  other	  independent	  variables	  such	  as	  age,	  gender,	  ethnicity,	  antipsychotic	  load	  or	  
estimated	  anticholinergic	  activity	  related	  to	  CTT?	  
	  
Background	  
Antipsychotic	  medications	  are	  effective	  agents	  in	  the	  treatment	  of	  schizophrenia	  and	  other	  
psychotic	  disorders,	  but	  their	  adverse	  effect	  profiles	  are	  considerable.	  	  
Gastrointestinal	   hypomotility	   is	   one	   commonly	   reported	   and	   potentially	   serious	   adverse	  
effect.	   The	   mechanism	   is	   usually	   considered	   to	   be	   anticholinergic	   inhibition	   of	  
gastrointestinal	  smooth	  muscle	  contraction	  and	  peristalsis	  (e.g.	  [1],	  [2]),	  but	  it	  is	  likely	  that	  
antipsychotic	  medications’	  antagonism	  of	  various	  serotonin	  receptor	  subtypes	  compounds	  
the	  problem	  [3]	  as	  serotonin	  plays	  a	  crucial	  role	  in	  gastrointestinal	  motility	  [4].	  	  
As	   a	   result	   of	   the	   pharmacological	   properties	   of	   clozapine	   and	   other	   antipsychotics,	   it	  
appears	  gastrointestinal	  motility	   is	  reduced.	   It	  has	  been	  hypothesised	  transit	  time	  through	  
the	   gut	   increases,	   resulting	   in	   the	   first	   instance	   in	   “slow	   transit”	   constipation,	   associated	  
with	   accumulation	   of	   faeces	   within	   the	   bowel	   and	   prolonged	   time	   between	   bowel	  
movements	  [3].	  Symptoms	  of	  slow	  transit	  constipation	  include	  low	  stool	  frequency,	  lack	  of	  
urge	  to	  defecate,	  abdominal	  distension,	  bloating,	  and	  abdominal	  discomfort	  [5].	  
	  
The	   exact	   mechanisms	   by	   which	   antipsychotics	   alter	   colonic	   anatomy	   have	   yet	   to	   be	  
elucidated.	   It	   is	   also	   unknown	   whether	   these	   antipsychotic-­‐induced	   colonic	   architectural	  
changes	  are	  reversible.	  Surprisingly,	  there	  are	  no	  published	  data	  on	  gastrointestinal	  motility	  
in	  antipsychotic	  treated	  patients.	  
	  
The	  earliest	  manifestation	  of	  gastrointestinal	  hypomotility	   is	  usually	  constipation,	  which	   is	  
reported	  in	  up	  to	  60%	  of	  clozapine-­‐treated	  patients	  [6]	  and	  in	  up	  to	  50%	  of	  patients	  treated	  
with	  other	  antipsychotics	  [2].	  	  
	  
There	   appear	   to	   be	   three	   main	   mechanisms	   whereby	   gastrointestinal	   hypomotility	   and	  
colonotoxic	   changes	   can	   progress	   to	   life-­‐threatening	   conditions.	   	   These	   involve	   the	  
accumulation	  of	  faeces	  within	  the	  bowel	  leading	  to	  distension,	  aspiration	  or	  infection	  [3].	  
	  
Antipsychotic-­‐treated	  patients	  with	  serious	  gastrointestinal	  hypomotility	  often	  under-­‐report	  
symptoms,	   present	   late	   and	  many	   fatal	   outcomes	   have	   been	   reported.	   Progression	   from	  
 
constipation	   to	   ileus,	   intestinal	  obstruction,	  bowel	   ischaemia,	  megacolon	  and	  death	   is	  not	  
uncommon	  in	  this	  cohort	  [3,	  7-­‐12].	  	  
	  
To	   date,	   there	   is	   little	   evidence-­‐based	   research	   on	   the	   management	   of	   gastrointestinal	  
hypomotility	   in	   antipsychotic-­‐treated	   patients.	   Although	   guidance	   exists	   to	   minimise	  
antipsychotic	   medications’	   adverse	   haematological	   [13,	   14],	   metabolic	   [15]	   and	   cardiac	  
effects	  [16],	  these	  guidelines	  do	  not	  emphasise	  the	  need	  to	  monitor	  (or	  treat	  constipation)	  
and	  its	  more	  serious	  sequelae.	  
	  
RESEARCH	  DESIGN	  AND	  METHODS	  	  
	  
Participants:	  	  	  
Participants	   will	   be	   recruited	   from	   inpatients	   residing	   in	   a	   New	   Zealand	   forensic	   and	  
rehabilitation	  service	  (total	  population	  of	  approximately	  100	  patients).	  Up	  to	  40	  patients	  will	  
be	   recruited.	   	   Participants	  will	   be	   approached	   in	   order	   determined	   by	   a	   random	   number	  
generator.	  
	  
Inclusion	  criteria:	  	  
Male	  and	  female	  adult	  patients	  (>18)	  prescribed	  antipsychotic	  medication	  (any	  dose),	  who	  
are	  able	  to	  provide	  informed	  consent.	  	  
	  
Exclusion	  criteria	  
Patients	  under	  the	  age	  of	  18,	  unable	  to	  provide	  informed	  consent	  or	  who	  do	  not	  understand	  
English	   will	   be	   excluded.	   We	   will	   also	   exclude	   patients	   with	   established	   gastrointestinal	  
hypomotility,	   or	   those	  who	   are	   taking	   laxatives	  which	   either	   they,	   or	   their	   treating	   team,	  
have	  concerns	  about	  withholding	  for	  the	  duration	  of	  the	  ROM	  test.	  The	  rationale	  for	  this	  is	  
to	  minimise	  risk	  to	  participants.	  
	  
Recruitment:	  
Recruitment	   is	   planned	   to	   commence	   Monday	   3	   March	   2014	   on	   and	   continue	   until	   40	  




Only	   patients	   competent	   to	   provide	   informed	   consent	   will	   be	   recruited	   (capacity	   will	   be	  
assessed	   by	   the	   researchers	   and	   checked	   with	   the	   treating	   psychiatrist).	   The	   informed	  
consent	  form	  is	  available	  on	  request.	  
	  
The	   investigator	   will	   initially	   spend	   approximately	   half	   an	   hour	   with	   each	   potential	  
participant	   explaining	   the	   project	   and	   consenting	   the	   patient.	   The	   investigator	   will	   go	  
through	  the	   information	  sheets,	  which	  have	  been	  designed	   for	   low	   levels	  of	   literacy,	  both	  
reading	  out	  the	  material	  and	  providing	  written	  material	  (appended).	  
	  
The	  exposure	  is	  the	  type	  and	  dose	  of	  antipsychotic	  treatment.	  
	  
The	  condition	  observed	  is	  colonic	  transit	  time	  as	  measured	  by	  ROM	  (Metcalf	  technique)	  
	  
 
Each	   participant	   will	   participate	   in	   the	   study	   for	   4-­‐7	   days.	   All	   treatment	   will	   continue	   as	  
usual,	   apart	   from	   bowel	   motility	   agents	   e.g.	   laxatives,	   which	   spuriously	   increase	   transit	  
times.	  These	  will	  need	  to	  be	  temporarily	  paused	  for	  two	  days	  prior	  to	  the	  ROM	  study	  until	  
its	   conclusion.	   	   The	   researchers	   will	   check	   this	   is	   acceptable	   to	   the	   participant	   and	   their	  
treating	  clinician.	  Rescue	  laxatives	  will	  be	  available	  if	  the	  participant	  requires	  them.	  
	  
The	   participant	   will	   be	   asked	   to	   swallow	   a	   small	   capsule	   containing	   radiopaque	   markers	  
(ROMs)	   on	   three	   consecutive	   days.	   ROMs	   are	   a	   simple,	   reliable	   method	   of	   measuring	  
gastrointestinal	  motility	  (Rao	  2005).	  Using	  the	  segmental	  method,	  the	  amount	  of	  time	  that	  
it	  takes	  to	  pass	  through	  each	  section	  of	  the	  intestinal	  tract	  can	  be	  tracked	  [17,	  18].	  On	  day	  1,	  
day	  2,	  and	  day	  3,	  the	  participants	  will	  swallow	  one	  capsule	  containing	  the	  ROMs.	  We	  will	  use	  
standardised	  ROMS	  called	  Sitzmarks.	  The	  soft	  gelatin	  capsule	  contain	  20	  ring-­‐shaped	  (4.5	  x	  
1.0	  mm)	  radiopaque	  markers	  made	  of	  polychlorinated	  vinyl	  with	  33%	  barium	  sulphate,	  are	  
tasteless	   and	   are	   taken	   by	   mouth	   with	   water.	   On	   day	   four	   the	   participant	   will	   have	   an	  
abdominal	   X-­‐ray	   to	   determine	   the	   location	   and	   extent	   of	   elimination	   of	   the	   radiopaque	  
markers.	  If	  more	  than	  two-­‐thirds	  of	  ROMs	  are	  retained	  (n=48),	  the	  X-­‐ray	  will	  be	  repeated	  on	  
day	   7.	   The	   total	   number	   of	   markers	   in	   each	   segment	   is	   used	   to	   determine	   transit	   time.	  
Transit	   times	   will	   be	   compared	   with	   population	   normative	   values	   (from	  meta-­‐analysis	   of	  
data	  from	  healthy	  controls).	  The	  researchers	  have	  chosen	  to	  use	  ROM	  method	  for	  studying	  
gastrointestinal	   motility	   despite	   some	   limitations	   and	   drawbacks	   including	   radiation	  
exposure	  (abdominal	  X-­‐ray).	  The	  alternatives	  are	  scintigraphy	  (also	  involving	  radiation)	  and	  
a	  newer	   technique	  using	  a	  wireless	  motility	   capsule	  are	   considerably	  more	  expensive	  and	  
not	  readily	  available	  in	  New	  Zealand.	  
	  
For	  consistency	  all	   the	  X-­‐rays	  will	  be	  read	   independently	  by	  SEP	  then	  by	  senior	  radiologist	  
MN	   (who	  will	   be	   blinded	   to	   clinical	   and	   demographic	   factors).	   Any	   disagreements	  will	   be	  
resolved	  by	  consensus.	  
	  
On	  Day	  4	  the	  participant	  will	  be	  asked	  to	  complete	  a	  bowel	  motility	  screen	  based	  on	  the	  
Rome	  III	  criteria.	  
	  
Main	  Outcome	  measures:	  
Primary	  outcome	  measure:	  colonic	  motility	  times,	  including	  segmental	  transit	  times	  (right	  
colon,	  left	  colon	  and	  rectosigmoid	  transit	  times)	  as	  measured	  by	  ROMs	  (Metcalf	  technique)	  
Continuous	  and	  categorical	  outcomes	  will	  be	  reported	  (i.e	  both	  transit	  time	  in	  hours,	  and	  
the	  proportion	  of	  patients	  diagnosed	  with	  gastrointestinal	  hypomotility.)	  Cut-­‐off	  points	  for	  
‘abnormal’	  motility	  tests	  are	  derived	  from	  meta-­‐analysis	  of	  normative	  data	  in	  healthy	  
controls	  and	  set	  at	  2SD	  above	  the	  population	  mean	  (i.e.	  colonic	  transit	  time	  of	  65	  hours	  or	  
more).	  
	  
Secondary	  outcome	  measure:	  subjective	  symptoms	  of	  constipation	  from	  a	  modified	  ROME	  
III	  questionnaire.	  
	  
Data	  Analysis:	  	  
A	  biostatistician	  (JS)	  is	  consulting	  on	  the	  statistical	  analysis	  for	  this	  project.	  	  
	  
 
Descriptive	   statistics	   (frequencies	   with	   confidence	   intervals,	   means	   with	   standard	  
deviations)	   will	   provide	   data	   summaries	   for	   bowel	   transit	   times.	   These	  will	   be	   compared	  
with	   normative	   population	   data.	   Continuous	   variables	   will	   be	   analysed	   using	   t-­‐tests	   or	  
ANOVA	   if	   data	  are	  normally	  distributed	  or	  Kruskall-­‐Wallis	   chi	   squared	  and	  median	   tests	   if	  
not	  normally	  distributed.	  
	  
Linear	   and	   logistic	   regression	   methods	   will	   then	   be	   used	   to	   examine	   which	   factors	   are	  
associated	  with	  the	  different	  transit	  times	  (age,	  sex,	  medication	  type	  and	  dose).	  	  
	  




Ethical	  approval	  for	  this	  research	  has	  been	  granted	  by	  the	  HDEC	  (reference	  13/CEN/153).	  
Consultation	  with	  Ngai	  Tahu	  has	  been	  undertaken	  through	  the	  University	  of	  Otago	  and	  
approval	  given.	  Consultation	  with	  consumer	  consultants	  has	  occurred.	  Site	  approval	  has	  
been	  given	  by	  Capital	  and	  Coast	  District	  Heath	  Board.	  
	  
Limitations	  of	  the	  research	  
 
The	   initial	   sample	  size	  of	  40	  participants	   is	   small.	   It	   is	  not	  possible	   to	  conduct	  a	  pre-­‐study	  
power	  analysis	  to	  determine	  how	  many	  patients	  are	  required	  to	  demonstrate	  a	  significant	  
difference	  in	  bowel	  motility	  if	  this	  exists,	  as	  there	  are	  no	  previous	  studies	  of	  this	  nature	  from	  
which	   to	  extrapolate	   likely	  effects.	   This	   study	  may	  be	  undepowered,	  but	  will	   be	  useful	   to	  
inform	  future	  research.	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